Food and Drug Administration (FDA) approval in May 2022 for type 2 diabetes, November 2023 for chronic weight management, and December 2024 for obstructive sleep apnea, marking it as the first approved therapy for this indication
Roth J, Glick SM, Yalow RS, Berson SA
Kangana Ranaut Questions Lack Of 'Dark Dusky' Actresses In Bollywood After Kajol: Too Much Glutathione Injections
Research Resources Browse the Research Library and Research Guides for educational content on research compounds, testing, storage, and quality control
In the ACHIEVE-3 Phase 3 trial, orforglipron was superior to oral semaglutide on both HbA1c reduction (approximately 2.2 vs 1.4 percentage points) and weight loss
Policy analysts cite a number of reasons for payers holding back, including cost